What are you looking for?
top

LEQVIO®▼ (inclisiran) mechanism of action video

Leqvio MOA video VIDEO

A video displaying the mechanism of action of LEQVIO®, the first and only siRNA LDL-C-lowering therapy.1-3

LDL-C, low-density lipoprotein cholesterol; siRNA, small interfering ribonucleic acid.

References

  1. LEQVIO® Summary of Product Characteristics.

  2. Stoekenbroek RM, et al. Future Cardiol 2018;14(6):433–442.

  3. Klinovski M, et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health.
     

UK | March 2025 | FA-11361470

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.